Universität zu Köln

Battista, Marco Johannes, Schmidt, Marcus ORCID: 0000-0003-1365-2414, Eichbaum, Michael, Almstedt, Katrin, Heimes, Anne-Sophie, Mallmann, Peter, Hoffmann, Gerald and Steiner, Eric (2015). Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch. Gynecol. Obstet., 292 (6). S. 1355 - 1361. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-0711

Full text not available from this repository.

Abstract

The available literature on the treatment options for recurrent or metastatic endometrial cancer (EC) is full of controversies. Therefore, we explore the results of the AGO pattern of care studies from the years 2013, 2009 and 2006. A questionnaire was developed and sent to all 682 German gynecological departments in 2013 (775 in 2009, 500 in 2006, respectively). The results of the questionnaires were compared with each other using Fisher's exact test. Responses were available in 40.0 % in 2013, 33.3 % in 2009 and 35.8 % in 2006. In 2013 the most preferred endocrine drug was progestin (79.8 %), followed by tamoxifen (42.8 %), aromatase inhibitor (19.8 %), fulvestrant (16.3 %) and a combination (3.9 %) (p < 0.001). 65.3, 59.8, 51.7 and 38.2 % of the participants used platinum, taxane, a combination of cytostatic drugs, anthracycline in metastatic EC, respectively (p = 0.215). 96.2, 92.7, 49.8 and 60.9 % of the participants performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013 because of a local recurrence, respectively (p < 0.001). Compared to 2009 and 2006 these rates remained stable (no p value < 0.05). Because of a distant metastasis 50.4, 64.2, 78.5 and 90.8 % of the participants performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013, respectively (p < 0.001). Compared to 2009 and 2006 more participants performed an operation or radiotherapy and less an endocrine treatment. Whereas progestin was the favorite drug, the participants of this study did not prefer a specific cytostatic drug for metastatic EC in 2013. This might have reflected the available literature, which did not provide a real standard of care.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Battista, Marco Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmidt, Marcus UNSPECIFIED orcid.org/0000-0003-1365-2414 UNSPECIFIED Eichbaum, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Almstedt, Katrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Heimes, Anne-Sophie UNSPECIFIED UNSPECIFIED UNSPECIFIED Mallmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, Gerald UNSPECIFIED UNSPECIFIED UNSPECIFIED Steiner, Eric UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-385755
DOI:	10.1007/s00404-015-3786-y
Journal or Publication Title:	Arch. Gynecol. Obstet.
Volume:	292
Number:	6
Page Range:	S. 1355 - 1361
Date:	2015
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-0711
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PHASE-II TRIAL; CARCINOMA; CHEMOTHERAPY; PACLITAXEL; SURVIVAL; TAMOXIFEN; ACETATE Multiple languages Obstetrics & Gynecology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/38575